A Phase 2 Study Assessing the Use of a Cancer DNA Blood Test to Reduce Chemotherapy Treatment for People With Hodgkin Lymphoma

Full Title

A Multicenter Study PRECISE-HL: Personalized Reduction of Chemotherapy Intensity through ctDNA Evaluation in Advanced Hodgkin Lymphoma

Purpose

Researchers want to see if a test for cancer DNA in the blood helps doctors decide whether to reduce Hodgkin lymphoma chemotherapy. The blood test is a circulating tumor DNA (ctDNA) test called Foresight CLARITY. ctDNA is genetic material released by tumor cells directly into the bloodstream.

Chemotherapy (like doxorubicin, vinblastine, and dacarbazine) is a standard treatment for Hodgkin lymphoma, but it can cause side effects. Reducing chemotherapy could ease the burden of these side effects.

If you join this study, you will get standard nivolumab immunotherapy and chemotherapy with doxorubicin, vinblastine, and dacarbazine. These drugs are given intravenously (by vein). During your treatment, we will test for ctDNA in your blood. Depending on the results of this testing, we may reduce the amount of chemotherapy you receive.

Contact

For more information about this study or to see if you can join, please call Dr. Alison Moskowitz’s office at 646-608-3726.